Cardiac Resynchronization Therapy CRT Market Overview
The Cardiac Resynchronization Therapy CRT Market is expanding as the prevalence of heart failure and cardiovascular diseases increases and healthcare providers adopt advanced cardiac devices. Growing awareness of CRT therapy, technological advancements, an aging population, favorable reimbursement policies, and increasing adoption of minimally invasive procedures are supporting market growth.
According to the WiseGuyReports market report published in August 2026, the global Cardiac Resynchronization Therapy CRT Market was valued at USD 3.92 Billion in 2023 and USD 4.22 Billion in 2024 and is projected to reach USD 7.7 Billion by 2032, registering a CAGR of 7.8%. The Transvenous implantation segment accounted for more than 85% of global revenue in 2024, while Lithium-ion batteries represented approximately 60% of market revenue.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/sample-request?id=643844
Key players driving innovation and competitiveness in the Cardiac Resynchronization Therapy CRT Market include:
Oscor
LivaNova
EP Technologies
GE Healthcare
St. Jude Medical
Boston Scientific
Sorin Group
Abbott Laboratories
Vitatron Medical
Endosense
Medtronic
Terumo
Biotronik
MicroPort
Baylis Medical
The market is being shaped by the rising prevalence of heart failure, increasing awareness of cardiac resynchronization therapy, and continued advances in implantable cardiac devices. Device miniaturization, remote patient monitoring, leadless and wireless CRT technologies, and AI-supported treatment planning are creating additional opportunities. Favorable reimbursement policies and expanding healthcare infrastructure are also supporting adoption across different regions.
The Cardiac Resynchronization Therapy CRT Market can be segmented by Implantation Site into Transvenous and Epicardial. By Device Type, it includes Cardiac Resynchronization Pacemakers (CRPs) and Cardiac Resynchronization Defibrillators (CRT-Ds). By Battery Type, it covers Lithium-ion (Li-ion) Batteries, Silver Oxide Batteries, and Nickel Zinc Batteries. By Procedure Type, it includes Open-heart Surgery and Minimally Invasive Surgery. Regionally, the market covers North America, Europe, South America, Asia Pacific, and the Middle East and Africa.
The growing need for advanced heart failure management is creating opportunities for medical-device manufacturers, hospitals, cardiology centers, and healthcare technology companies. Leadless and wireless CRT systems, remote monitoring, AI-enabled cardiac care, minimally invasive implantation techniques, and personalized therapy can support market development and future growth.
Recent Developments and Market Trends:
The rising prevalence of heart failure is increasing demand for cardiac resynchronization therapy and related implantable devices.
Transvenous implantation remains widely adopted because of its minimally invasive nature and established use among healthcare providers.
Minimally invasive surgical techniques are gaining attention as they can reduce trauma, hospital stays, and recovery time compared with traditional open-heart procedures.
Remote patient monitoring is becoming increasingly important, allowing physicians to monitor patients and adjust therapy remotely.
Leadless and wireless CRT technologies are emerging as areas of innovation aimed at improving device design and implantation options.
Artificial intelligence and machine learning are being explored to support more accurate diagnosis, personalized treatment planning, and optimization of CRT therapy.
Recent industry developments highlighted by WiseGuyReports include Abbott’s launch of the Aveir VR CRT-D in March 2023, Medtronic’s FDA approval for the Micra AV CRT-P in February 2023, and a reported Boston Scientific collaboration with Apple in January 2023 focused on integrating CRT devices with Apple Watch-based remote patient monitoring.
Reasons to Buy the Report:
Provides comprehensive insights into the Cardiac Resynchronization Therapy CRT Market dynamics, trends, opportunities, and growth potential.
Helps identify opportunities across transvenous and epicardial implantation approaches, CRT pacemakers, and CRT defibrillators.
Offers detailed segmentation analysis across implantation site, device type, battery type, procedure type, and geographic markets.
Includes competitive intelligence covering leading cardiac-device, medical-device, and healthcare technology companies.
Supports informed decisions using market forecasts, heart failure trends, technological advancements, remote monitoring adoption, reimbursement developments, and regional opportunities.
Future Outlook:
The future of the Cardiac Resynchronization Therapy CRT Market will be shaped by the rising prevalence of heart failure, increasing cardiovascular disease burden, an aging population, advances in implantable devices, remote monitoring, and minimally invasive cardiac procedures. The Transvenous segment accounted for more than 85% of global market revenue in 2024, while the Minimally Invasive Surgery segment is projected to reach USD 2.3 Billion by 2032 at an 8.5% CAGR. North America holds a significant market position, while Asia Pacific is expected to experience substantial growth as healthcare expenditure and access to advanced cardiac technologies increase. The global Cardiac Resynchronization Therapy CRT Market is projected to reach USD 7.7 Billion by 2032 at a CAGR of 7.8%.
➤➤Explore Our Latest Related Reports:
